ABSTRACTS - World Psychiatric Association

PO1.22.
ASSOCIATION BETWEEN DURATION
OF UNTREATED PSYCHOSIS AND REMISSION
IN SUBJECTS WITH SCHIZOPHRENIA
OR SCHIZOAFFECTIVE DISORDER TREATED
WITH LONG-ACTING INJECTABLE RISPERIDONE:
A 52-WEEK ITALIAN STUDY
G. Giardina, A. Rossi, M.G. Giustra, M.M. Bernareggi, on behalf
of Risperidone Long-Acting Trial Italian Investigators
Mental Health Department, Taranto; Department of Experimental
Medicine, University of L’Aquila; Medical Affairs, Janssen-Cilag,
Cologno Monzese, Milan, Italy
The duration of untreated psychosis (DUP) is the time from the first
psychotic symptom to initiation of treatment. A longer DUP leads to
a poorer prognosis and a reduced likelihood of achieving remission.
The objective of this analysis from an open label, single-arm 1-year
trial with long-acting injectable risperidone (RLAI) was to investigate
in a subset of subjects with different DUP which factors are predictors
of remission. DUP was categorised in